GLP-1 vs. Insulin: Key Differences Explained

Q: What compounded GLP-1 options does PlexusDx offer?

PlexusDx provides compounded semaglutide injection ($179–$229/mo), oral semaglutide ($249/mo), tirzepatide injection ($229–$309/mo), and oral tirzepatide ($229–$509/mo) from licensed 503A compounding pharmacies.

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, GLP-1 is not insulin—these are two fundamentally different hormones that regulate blood sugar through distinct biological pathways. GLP-1 (glucagon-like peptide-1) is an incretin hormone that increases insulin secretion in response to food, while insulin itself directly lowers glucose levels.

This distinction matters significantly for treatment planning. Understanding how GLP-1 functions helps patients evaluate whether compounded GLP-1 therapy, oral formulations, or other options might align with their metabolic needs and provider recommendations.

The Fundamental Difference: Hormone Classification and Origin

GLP-1 is an incretin hormone produced by intestinal L-cells in response to nutrient intake, primarily glucose. Insulin is produced by pancreatic beta cells and circulates continuously to maintain baseline glucose homeostasis. Both regulate blood sugar, but through distinct mechanisms.

GLP-1 works indirectly by stimulating the pancreas to release insulin when needed, while insulin acts directly on muscle, fat, and liver cells to facilitate glucose uptake. This indirect versus direct action explains why GLP-1 typically causes less hypoglycemia risk when used alone.

How GLP-1 and Insulin Differ: A Clinical Comparison Framework

This comparison framework highlights the key physiological and clinical differences between GLP-1 and insulin, which can help inform provider conversations about treatment selection and mechanism-of-action considerations.

Characteristic	GLP-1	Insulin
Hormone Type	Incretin (glucose-dependent)	Direct glucose regulator
Source	Intestinal L-cells (secreted after eating)	Pancreatic beta cells (constitutive release)
Primary Mechanism	Stimulates pancreatic insulin release; slows gastric emptying	Direct glucose uptake into cells
Hypoglycemia Risk	Low when used alone (glucose-dependent)	Moderate to high risk without monitoring
Onset of Action	Minutes to hours (postprandial response)	Minutes to hours (depends on insulin type)
Clinical Use Cases	Type 2 diabetes, weight management support	Type 1 diabetes, advanced type 2 diabetes

Why GLP-1's Secondary Actions Matter for Treatment Planning

Beyond glucose regulation, GLP-1 influences satiety signaling, gastric motility, and potentially cardiovascular outcomes. Compounded GLP-1 injections and oral formulations leverage these multi-system effects, which may differ from insulin's glucose-focused mechanism alone.

These secondary actions—delayed gastric emptying, appetite reduction, incretin effect—are why providers may recommend GLP-1 therapy even when insulin secretion capacity remains relatively intact. PlexusDx compounded options range from microdose protocols at $129/month to full-strength injections at $149/mo.

Who Qualifies for GLP-1 vs. Insulin: Provider Evaluation Framework

GLP-1 therapy is typically considered for type 2 diabetes and weight management support in patients with adequate residual pancreatic function. Insulin becomes necessary when beta-cell reserve is severely compromised, as occurs in advanced type 2 diabetes or type 1 diabetes.

A qualified provider evaluates C-peptide levels, hemoglobin A1c, metabolic biomarkers, and kidney function before recommending GLP-1 or insulin. Genetic predispositions in GLP-1 receptor and GIPR pathways may provide additional context for personalized treatment selection.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by identifying predispositions in GLP-1 receptor (rs6923761) and GIPR (rs1800437) genetic variants. These variants relate to baseline incretin pathway activity and may support more informed provider conversations about GLP-1 responsiveness.

The genetic test reveals predispositions in peptide metabolic pathways, not exact medication response or insulin need. Results should be interpreted alongside clinical biomarkers, glucose patterns, and provider assessment to guide treatment selection appropriately.

Understanding your genetic predispositions in GLP-1 and GIPR pathways—combined with metabolic biomarkers—can support a more personalized conversation with your provider about whether compounded GLP-1 therapy, oral formulations, or other options align with your individual physiology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I use GLP-1 if my pancreas still produces insulin?

Yes. GLP-1 works by stimulating your pancreas to release insulin when needed. It typically requires adequate residual pancreatic function, which most type 2 diabetes patients retain. Your provider will evaluate C-peptide and other markers.

Why is GLP-1 safer than insulin regarding low blood sugar?

GLP-1's glucose-dependent mechanism means it only stimulates insulin release when blood sugar is elevated. Insulin, by contrast, lowers glucose regardless of meal timing, carrying higher hypoglycemia risk without careful monitoring and dosing.

What compounded GLP-1 options does PlexusDx offer?

PlexusDx provides compounded semaglutide injection ($149/mo), oral semaglutide ($249/mo), tirzepatide injection ($249/mo), and oral tirzepatide ($279/mo) from licensed 503A compounding pharmacies.

When would a provider recommend insulin over GLP-1?

Insulin is recommended when pancreatic beta-cell function is severely compromised, as in advanced type 2 or type 1 diabetes. Fasting glucose, C-peptide levels, and clinical presentation guide this decision with your healthcare team.

Does the Precision Peptide Genetic Test predict if GLP-1 will work for me?

No. The test identifies predispositions in GLP-1 receptor and GIPR pathways that may provide context for provider discussions, but genetics alone do not predict exact medication response. Clinical evaluation and biomarkers are essential.

Is GLP-1 Insulin? The Answer Isn’t What You Think